PAINTS STOCKS
ASIAN PAINTS Says
New 3.5% Price Hike Announced For November
ASIAN PAINTS Says
New 3.5% Price Hike Announced For November
VARUN BEVERAGES:
Q2 VOLUME GROWTH OF 28.7% VS FY27 TARGETS DOUBLE-DIGIT VOLUME GROWTH
Q2 VOLUME GROWTH OF 28.7% VS FY27 TARGETS DOUBLE-DIGIT VOLUME GROWTH
XCHANGING SOLUTIONS Q2 FY27 RESULTS (CONSOLIDATED)
β’ Net Profit: βΉ15.19 Cr β6.58% (YoY) | β0.46% (QoQ)
β’ Revenue: βΉ53.21 Cr β0.76% (YoY) | β0.80% (QoQ)
β’ EBITDA: βΉ18.43 Cr β8.35% (YoY) | β2.45% (QoQ)
β’ EBITDA Margin: 34.64% vs 32.21% (YoY) | 33.54% (QoQ)
β’ Net Profit: βΉ15.19 Cr β6.58% (YoY) | β0.46% (QoQ)
β’ Revenue: βΉ53.21 Cr β0.76% (YoY) | β0.80% (QoQ)
β’ EBITDA: βΉ18.43 Cr β8.35% (YoY) | β2.45% (QoQ)
β’ EBITDA Margin: 34.64% vs 32.21% (YoY) | 33.54% (QoQ)
RESONANCE SPECIALTIES Q2 FY27 RESULTS (STANDALONE)
β’ Net Profit: βΉ8 Cr β411% (YoY) | β47% (QoQ)
β’ Revenue: βΉ34 Cr β59% (YoY) | β5% (QoQ)
β’ EBITDA: βΉ11 Cr β362% (YoY) | β46% (QoQ)
β’ EBITDA Margin: 31.8% vs 11.0% (YoY) | 22.9% (QoQ)
β’ Net Profit: βΉ8 Cr β411% (YoY) | β47% (QoQ)
β’ Revenue: βΉ34 Cr β59% (YoY) | β5% (QoQ)
β’ EBITDA: βΉ11 Cr β362% (YoY) | β46% (QoQ)
β’ EBITDA Margin: 31.8% vs 11.0% (YoY) | 22.9% (QoQ)
GUJARAT CONTAINERS Q2 FY27 RESULTS
β’ Net Profit: βΉ4.06 Cr β199.14% (YoY) | β7.92% (QoQ)
β’ Revenue: βΉ44.47 Cr β21.30% (YoY) | β4.52% (QoQ)
β’ EBITDA: βΉ6.03 Cr β132.24% (YoY) | β5.33% (QoQ)
β’ EBITDA Margin: 13.55% vs 7.08% (YoY) | 12.28% (QoQ)
β’ Net Profit: βΉ4.06 Cr β199.14% (YoY) | β7.92% (QoQ)
β’ Revenue: βΉ44.47 Cr β21.30% (YoY) | β4.52% (QoQ)
β’ EBITDA: βΉ6.03 Cr β132.24% (YoY) | β5.33% (QoQ)
β’ EBITDA Margin: 13.55% vs 7.08% (YoY) | 12.28% (QoQ)
KIRLFER: Q2 SL NET PROFIT 976M RUPEES VS 885M (YOY)
KIRLFER: Q2 EBITDA 2.23B RUPEES VS 2.14B (YOY); Q2 EBITDA MARGIN 10.9% VS 12.36% (YOY)
KIRLFER: Q2 REVENUE 20.5B RUPEES VS 17.28B (YOY)
KIRLFER: Q2 EBITDA 2.23B RUPEES VS 2.14B (YOY); Q2 EBITDA MARGIN 10.9% VS 12.36% (YOY)
KIRLFER: Q2 REVENUE 20.5B RUPEES VS 17.28B (YOY)
SHARDACROP: Q2 CONS NET PROFIT 918M RUPEES VS 743M (YOY)
SHARDACROP: Q2 EBITDA 1.64B RUPEES VS 1.33B (YOY); Q2 EBITDA MARGIN 15.6% VS 14.3% (YOY)
SHARDACROP: Q2 REVENUE 10.5B RUPEES VS 9.3B (YOY)
SHARDACROP: Q2 EBITDA 1.64B RUPEES VS 1.33B (YOY); Q2 EBITDA MARGIN 15.6% VS 14.3% (YOY)
SHARDACROP: Q2 REVENUE 10.5B RUPEES VS 9.3B (YOY)
Bazaar.Updateπ
WELSPUNLIV: Q2 CONS NET PROFIT 1.7B RUPEES VS 130M (YOY)
WELSPUNLIV: Q2 REVENUE 28.4B RUPEES VS 24.4B (YOY)
WELSPUNLIV: Q2 EBITDA 3.38B RUPEES VS 1.53B (YOY); Q2 EBITDA MARGIN 11.9% VS 6.3% (YOY)
β€2
SPORTKING: Q2 SL NET PROFIT 964M RUPEES VS 283M (YOY)
SPORTKING: Q2 REVENUE 7.8B RUPEES VS 6.3B (YOY)
SPORTKING: Q2 REVENUE 7.8B RUPEES VS 6.3B (YOY)
SPORTKING: Q2 EBITDA 1.55B RUPEES VS 654M (YOY); Q2 EBITDA MARGIN 19.8% VS 10.4% (YOY)
TATA CHEMICALS, TATA INVESTMENT; Noel Tata Proposes Merging Tata Elec Sys & Tata Consulting Engineers Into Tata Sons - CNBC-TV18 π΄π΄
Noel Tata writes to Tata Sons board
Seeks 2 items on agenda for Nov 26 board meeting
Noel Tata writes to Tata Sons board
Seeks 2 items on agenda for Nov 26 board meeting
π2
TATA CHEMICALS, TATA INVESTMENT: NOEL Tata Aim Is To Cease Tata Sons Being An NBFC & A Core Investment Company - CNBC-TV18 π΄π΄
π1
DHANUKA AGRITECH Q2 FY27 (STANDALONE) ; NET PROFIT UP 16% AT βΉ109 CR (YOY), UP 201% (QOQ)
REVENUE UP 10% AT βΉ658 CR (YOY), UP 42% (QOQ)
EBITDA UP 12% AT βΉ153 CR (YOY), UP 178% (QOQ)
MARGINS AT 23.3% VS 22.9% (YOY), 11.9% (QOQ)
REVENUE UP 10% AT βΉ658 CR (YOY), UP 42% (QOQ)
EBITDA UP 12% AT βΉ153 CR (YOY), UP 178% (QOQ)
MARGINS AT 23.3% VS 22.9% (YOY), 11.9% (QOQ)
ABCAPITAL: Q2 CONS NET PROFIT 13B RUPEES VS 8.5B (YOY)
ABCAPITAL: Q2 REVENUE 140B RUPEES VS 106B (YOY)
ABCAPITAL: Q2 REVENUE 140B RUPEES VS 106B (YOY)
ABCAPITAL: CO'S CONSOLIDATED REVENUE GREW BY 31% YOY TO βΉ 16,545 CRORE IN Q2 FY27
ADITYA BIRLA CAPITAL Q2 FY27 (CONS.) ; NET PROFIT UP 38% AT βΉ1,288 CR (YOY), UP 10% (QOQ)
NII UP 28% AT βΉ2,817 CR (YOY), UP 9% (QOQ)
INSURANCE PREMIUM UP 37 % TO 7198 CR YOY, UP 26 % QOQ
NII UP 28% AT βΉ2,817 CR (YOY), UP 9% (QOQ)
INSURANCE PREMIUM UP 37 % TO 7198 CR YOY, UP 26 % QOQ
EMAMIPAP: Q2 SL NET PROFIT 444M RUPEES VS 66M (YOY)
EMAMIPAP: Q2 EBITDA 929M RUPEES VS 363M (YOY); Q2 EBITDA MARGIN 15.76% VS 8.1% (YOY)
EMAMIPAP: Q2 EBITDA 929M RUPEES VS 363M (YOY); Q2 EBITDA MARGIN 15.76% VS 8.1% (YOY)
SUNPHARMA: Q2 CONS PBT 44B RUPEES VS 42BB (YOY); CO HAS AN EXCEPTIONAL ITEM OF 12.7B RUPEES
β€1